887583-52-0

Usage

Uses

Used in Pharmaceutical Synthesis:
6-(Trifluoromethyl)pyridine-2-carbonitrile serves as a crucial intermediate in the synthesis of various pharmaceuticals. Its unique structure and functional groups contribute to the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Production:
6-(trifluoromethyl)pyridine-2-carbonitrile is also utilized as an intermediate in the production of agrochemicals, where it plays a vital role in the synthesis of active ingredients for pesticides and other agricultural chemicals. Its properties allow for the creation of more effective and targeted agrochemicals.
Used in Organic Synthesis Reactions:
Due to its reactivity and the presence of the carbonitrile group, 6-(Trifluoromethyl)pyridine-2-carbonitrile is employed in various organic synthesis reactions. It can be further functionalized to produce a wide array of chemical compounds for different applications.
Used in Research and Development:
In the field of chemical research and development, 6-(Trifluoromethyl)pyridine-2-carbonitrile is an important compound for exploring new chemical reactions and developing innovative synthetic pathways. Its unique properties make it a valuable tool for advancing scientific understanding and creating new chemical entities.

InChI:InChI=1/C7H3F3N2/c8-7(9,10)6-3-1-2-5(4-11)12-6/h1-3H

Upstream product

• 122918-25-6 6-bromopyridin-2-carbonitrile 
• 189278-27-1 2-bromo-6-(trifluoromethyl)pyridine 

Downstream Products

• 131747-42-7 6-(trifluoromethyl)pyridine-2-carboxylic acid 
• 155377-05-2 6-(trifluoromethyl)pyridine-2-carboxylic acid methyl ester 
• 1446507-38-5 6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine-2,4-(1H,3H)-dione 
• 1446507-40-9 2,4-dichloro-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazine 
• 1446507-68-1 4-chloro-6-(6-(trifluoromethyl)pyridin-2-yl)-N-(2-(trifluoro-methyl)-pyridin-4-yl)-1,3,5-triazin-2-amine 
• 1446502-11-9 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol 
• 1269626-16-5 5-(2-Fluoro-benzyl)-2-(6-trifluoromethyl-pyridin-2-yl)-pyrimidine-4,6-diamine 

Relevant academic research and scientific papers

Compound with IDH mutant inhibitory activity, preparation method and application thereof

The invention belongs to the field of medicines, and particularly relates to a s-triazine compound with structural characteristics of a general formula I or a pharmaceutically acceptable salt thereof,a pharmaceutical composition and a preparation method thereof, and application of the s-triazine compound or the pharmaceutically acceptable salt and the pharmaceutical composition in preparation ofIDH2 mutant inhibitors. According to the invention, pharmacological experiment results show that the compound disclosed by the invention has an obvious inhibition effect on the activity of an IDH2 mutant (mIDH2), can effectively inhibit the process that alpha-ketoglutaric acid is catalyzed by mIDH2 to generate 2-hydroxyglutaric acid, and can be used for preparing drugs for preventing and/or treating various related diseases caused by IDH2 mutation, wherein the diseases comprise cancers carrying IDH2 mutation.

Decarboxylative Trifluoromethylating Reagent [Cu(O2CCF3)(phen)] and Difluorocarbene Precursor [Cu(phen)2][O2CCF2Cl]

This article describes the new economic decarboxylative trifluoromethylating reagent [Cu(phen)(O2CCF3)] (1; phen=1,10-phenanthroline) and the efficient difluorocarbene precursor [Cu(phen)2][O2CCF2Cl] (2). Treatment of copper tert-butoxide with phen and subsequent addition of trifluoroacetic acid or chlorodifluoroacetic acid afforded air-stable complexes 1 and 2, respectively, which were characterized by X-ray crystallography. The copper(I) ion in 1 is coordinated by a bidentate phen ligand, a monodentate trifluoroacetate group, and a molecule of CH3CN in a distorted tetrahedral coordination geometry. The molecular structure of 2 adopts an ionic form that consists of a [Cu(phen)2]+ cation and a chlorodifluoroacetate anion. Complex 1 reacted with a variety of aryl and heteroaryl halides to form trifluoromethyl (hetero)arenes in good yields. The corresponding Hammett plot exhibited a linear relationship and a reaction parameter (ρ)=+0.56±0.02, which indicated that the trifluoromethylation reaction proceeded via a nucleophilic reactive species. Complex 2 reacts with phenols to produce aryl difluoromethyl ethers in modest-to-excellent yields. Mechanistic investigations revealed that the difluoromethylation reaction proceeds by initial copper-mediated formation of difluorocarbene and subsequent concerted addition of difluorocarbene to the phenol to form a three-center transition state.

Copper-mediated perfluoroalkylation of heteroaryl bromides with (phen)CuRF

The attachment of perfluoroalkyl groups onto organic compounds has been a major synthetic goal over the past several decades. Previously, our group reported phenanthroline-ligated perfluoroalkyl copper reagents, (phen)CuR F, which react with aryl iodides and aryl boronates to form the corresponding benzotrifluorides. Herein the perfluoroalkylation of a series of heteroaryl bromides with (phen)CuCF3 and (phen)CuCF 2CF3 is reported. The mild reaction conditions allow the process to tolerate many common functional groups. Perfluoroethylation with (phen)CuCF2CF3 occurs in somewhat higher yields than trifluoromethylation with (phen)CuCF3, creating a method to generate fluoroalkyl heteroarenes that are less accessible from trifluoroacetic acid derivatives.

Novel Pyrimidine- And Triazine-Hepcidine Antagonists

The present invention relates to new hepcidin antagonists, pharmaceutical compositions containing them and the use thereof as a drug, in particular for the treatment of iron metabolism disorders such as, in particular, iron deficiency diseases and anaemia, in particular anaemia associated with chronic inflammatory disease (ACD: anaemia of chronic disease and AI: anaemia of inflammation).

HETEROBICYCLIC METALLOPROTEASE INHIBITORS

The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP- 13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP- 13 inhibitors.